B.Riley analyst Mayank Mamtani reiterated a Buy rating and $66.00 price target on Cytokinetics (NASDAQ: CYTK).The analyst comments "On ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

Wall Street bullish on Cytokinetics (CYTK) following positive trial resultsDecember 28, 2023 7:55 AM Cytokinetics (CYTK) PT Raised to $86 at Truist, 'recent data further support CYTK as an attractive M&A target'December 27, 2023 1:43 PM Cytokinetics (CYTK) PT Raised to $107 at Oppenheimer, 'We Stay Bullish'December 27, 2023 1:42 PM Oppenheimer on Cytokinetics (CYTK): 'We stay bullish'December 27, 2023 9:23 AM Mizuho on Cytokinetics (CYTK): 'Investors will now likely shift the debate back to M&A'December 27, 2023 9:21 AM Truist on Cytokinetics (CYTK): 'We See Best In Class Potential for aficamten'December 27, 2023 9:20 AM Form 8-K CYTOKINETICS INC For: Dec 27December 27, 2023 7:31 AM Cytokinetics (CYTK) Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic CardiomyopathyDecember 27, 2023 7:30 AM Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic CardiomyopathyDecember 27, 2023 7:30 AM Cytokinetics (CYTK) to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with HCMDecember 26, 2023 4:01 PM Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic CardiomyopaDecember 26, 2023 4:00 PM